# A Clinical Study of HT-101 and HT-102 in Patients With Chronic Hepatitis B Virus Infection

> **NCT07245953** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **Suzhou HepaThera Biotech Co., Ltd.** · enrollment: 60 (estimated)

## Conditions studied

- Chronic Hepatitis B

## Interventions

- **DRUG:** HT-101
- **DRUG:** HT-102
- **DRUG:** HT-101 placebo
- **DRUG:** HT-102 placebo

## Key facts

- **NCT ID:** NCT07245953
- **Lead sponsor:** Suzhou HepaThera Biotech Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2025-11-05
- **Primary completion:** 2027-02
- **Final completion:** 2027-05
- **Target enrollment:** 60 (ESTIMATED)
- **Last updated:** 2025-11-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07245953

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07245953, "A Clinical Study of HT-101 and HT-102 in Patients With Chronic Hepatitis B Virus Infection". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT07245953. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*